1
|
Kumar V, Boorman J, Greenlee WJ, Zeng X, Lin J, van den Akker F. Exploring the inhibition of the soluble lytic transglycosylase Cj0843c of Campylobacter jejuni via targeting different sites with different scaffolds. Protein Sci 2023:e4683. [PMID: 37209283 DOI: 10.1002/pro.4683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 05/04/2023] [Accepted: 05/14/2023] [Indexed: 05/22/2023]
Abstract
Bacterial lytic transglycosylases (LTs) contribute to peptidoglycan cell wall metabolism and are potential drug targets to potentiate β-lactam antibiotics to overcome antibiotic resistance. Since LT inhibitor development is underexplored, we probed fifteen N-acetyl-containing heterocycles in a structure-guided fashion for their ability to inhibit and bind to the Campylobacter jejuni LT Cj0843c. Ten GlcNAc analogs were synthesized with substitutions at the C1 position, with two having an additional modification at the C4 or C6 position. Most of the compounds showed weak inhibition of Cj0843c activity. Compounds with alterations at the C4 position, replacing the -OH with a -NH2 , and C6 position, the addition of a -CH3 , yielded improved inhibitory efficacy. All ten GlcNAc analogs were crystallographically analyzed via soaking experiments using Cj0843c crystals and found to bind to the +1 +2 saccharide subsites with one of them additionally binding to the -2 -1 subsite region. We also probed other N-acetyl-containing heterocycles and found that sialidase inhibitors N-acetyl-2,3-dehydro-2-deoxyneuraminic acid and siastatin B inhibited Cj0843c weakly and crystallographically bound to the -2 -1 subsites. Analogs of the former also showed inhibition and crystallographic binding and included zanamivir amine. This latter set of heterocycles positioned their N-acetyl group in the -2 subsite with additional moieties interacting in the -1 subsite. Overall, these results could provide novel opportunities for LT inhibition via exploring different subsites and novel scaffolds. The results also increased our mechanistic understanding of Cj0843c regarding peptidoglycan GlcNAc subsite binding preferences and ligand-dependent modulation of the protonation state of the catalytic E390. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Vijay Kumar
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, USA
| | - Jacob Boorman
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, USA
| | | | - Ximin Zeng
- Department of Animal Science, University of Tennessee, Knoxville, TN, USA
| | - Jun Lin
- Department of Animal Science, University of Tennessee, Knoxville, TN, USA
| | - Focco van den Akker
- Department of Biochemistry, Case Western Reserve University, Cleveland, OH, USA
| |
Collapse
|
2
|
Zhou HL, Hausladen A, Anand P, Rajavel M, Stomberski CT, Zhang R, Premont RT, Greenlee WJ, van den Akker F, Stamler JS. Identification of a Selective SCoR2 Inhibitor That Protects Against Acute Kidney Injury. J Med Chem 2023; 66:5657-5668. [PMID: 37027003 PMCID: PMC10416317 DOI: 10.1021/acs.jmedchem.2c02089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023]
Abstract
Acute kidney injury (AKI) is associated with high morbidity and mortality, and no drugs are available clinically. Metabolic reprogramming resulting from the deletion of S-nitroso-coenzyme A reductase 2 (SCoR2; AKR1A1) protects mice against AKI, identifying SCoR2 as a potential drug target. Of the few known inhibitors of SCoR2, none are selective versus the related oxidoreductase AKR1B1, limiting therapeutic utility. To identify SCoR2 (AKR1A1) inhibitors with selectivity versus AKR1B1, analogs of the nonselective (dual 1A1/1B1) inhibitor imirestat were designed, synthesized, and evaluated. Among 57 compounds, JSD26 has 10-fold selectivity for SCoR2 versus AKR1B1 and inhibits SCoR2 potently through an uncompetitive mechanism. When dosed orally to mice, JSD26 inhibited SNO-CoA metabolic activity in multiple organs. Notably, intraperitoneal injection of JSD26 in mice protected against AKI through S-nitrosylation of pyruvate kinase M2 (PKM2), whereas imirestat was not protective. Thus, selective inhibition of SCoR2 has therapeutic potential to treat acute kidney injury.
Collapse
Affiliation(s)
- Hua-Lin Zhou
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - Alfred Hausladen
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - Puneet Anand
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - Malligarjunan Rajavel
- Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
| | - Colin T. Stomberski
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - Rongli Zhang
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - Richard T. Premont
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - William J. Greenlee
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| | - Focco van den Akker
- Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
| | - Jonathan S. Stamler
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA 44106
- Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA 44106
| |
Collapse
|
3
|
Sato T, Andrade CDC, Yoon SH, Zhao Y, Greenlee WJ, Weber PC, Viswanathan U, Kulp J, Brooks DJ, Demay MB, Bouxsein ML, Mitlak B, Lanske B, Wein MN. Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice. Proc Natl Acad Sci U S A 2022; 119:e2214396119. [PMID: 36472957 PMCID: PMC9897432 DOI: 10.1073/pnas.2214396119] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 11/11/2022] [Indexed: 12/12/2022] Open
Abstract
Osteoporosis is a major public health problem. Currently, there are no orally available therapies that increase bone formation. Intermittent parathyroid hormone (PTH) stimulates bone formation through a signal transduction pathway that involves inhibition of salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3). Here, we further validate SIK2/SIK3 as osteoporosis drug targets by demonstrating that ubiquitous deletion of these genes in adult mice increases bone formation without extraskeletal toxicities. Previous efforts to target these kinases to stimulate bone formation have been limited by lack of pharmacologically acceptable, specific, orally available SIK2/SIK3 inhibitors. Here, we used structure-based drug design followed by iterative medicinal chemistry to identify SK-124 as a lead compound that potently inhibits SIK2 and SIK3. SK-124 inhibits SIK2 and SIK3 with single-digit nanomolar potency in vitro and in cell-based target engagement assays and shows acceptable kinome selectivity and oral bioavailability. SK-124 reduces SIK2/SIK3 substrate phosphorylation levels in human and mouse cultured bone cells and regulates gene expression patterns in a PTH-like manner. Once-daily oral SK-124 treatment for 3 wk in mice led to PTH-like effects on mineral metabolism including increased blood levels of calcium and 1,25-vitamin D and suppressed endogenous PTH levels. Furthermore, SK-124 treatment increased bone formation by osteoblasts and boosted trabecular bone mass without evidence of short-term toxicity. Taken together, these findings demonstrate PTH-like effects in bone and mineral metabolism upon in vivo treatment with orally available SIK2/SIK3 inhibitor SK-124.
Collapse
Affiliation(s)
- Tadatoshi Sato
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA01655
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA01655
| | | | - Sung-Hee Yoon
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
| | - Yingshe Zhao
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
| | | | - Patricia C. Weber
- Harrington Discovery Institute, University Hospitals, Cleveland, OH44106
| | | | | | - Daniel J. Brooks
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
| | - Marie B. Demay
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
| | - Mary L. Bouxsein
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
| | | | | | - Marc N. Wein
- Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114
- Broad Institute of MIT and Harvard, Cambridge, MA02142
- Harvard Stem Cell Institute, Cambridge, MA02138
| |
Collapse
|
4
|
Mandal M, Madeira M, Amin R, Buevich AV, Cheng A, Labroli M, Liu X, Acton J, Pio B, Basso A, Chobanian H, Dong G, Dropinski J, Guo Y, Guo Z, Kurowski S, Korfmacher W, Lee S, Meng D, Ondeyka D, Yang Z, Zhang R, Wei H, Wu Z, Zhang F, Wollenberg G, Biftu T, Greenlee WJ, Chintala M, Maletic M, Zhu Z. Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery. J Med Chem 2022; 65:5575-5592. [DOI: 10.1021/acs.jmedchem.1c02048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Jayne CL, Andreani T, Chan TY, Chelliah MV, Clasby MC, Dwyer M, Eagen KA, Fried S, Greenlee WJ, Guo Z, Hawes B, Hruza A, Ingram R, Keertikar KM, Neelamkavil S, Reichert P, Xia Y, Chackalamannil S. Discovery of hydroxy pyrimidine Factor IXa inhibitors. Bioorg Med Chem Lett 2020; 30:127279. [PMID: 32527459 DOI: 10.1016/j.bmcl.2020.127279] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/16/2020] [Accepted: 05/18/2020] [Indexed: 10/24/2022]
Abstract
The synthesis and structure activity relationship development of a pyrimidine series of heterocyclic Factor IXa inhibitors is described. Increased selectivity over Factor Xa inhibition was achieved through SAR expansion of the P1 element. Select compounds were evaluated in vivo to assess their plasma levels in rat.
Collapse
Affiliation(s)
- Charles L Jayne
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
| | - Teresa Andreani
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Tin-Yau Chan
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | | | - Martin C Clasby
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Michael Dwyer
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Keith A Eagen
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Steve Fried
- Department of Biology, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - William J Greenlee
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Zhuyan Guo
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Brian Hawes
- Department of Biology, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Alan Hruza
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Richard Ingram
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Kartik M Keertikar
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | | | - Paul Reichert
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Yan Xia
- Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | | |
Collapse
|
6
|
Neelamkavil SF, Stamford AW, Kowalski T, Biswas D, Boyle C, Chackalamannil S, Xia Y, Jayne C, Neustadt B, Hao J, Liu H, Dai X, Baker H, Hawes B, O’Neill K, Tang H, Greenlee WJ. Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes. ACS Med Chem Lett 2018; 9:457-461. [PMID: 29795759 PMCID: PMC5949837 DOI: 10.1021/acsmedchemlett.8b00073] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Accepted: 04/10/2018] [Indexed: 11/30/2022] Open
Abstract
The ever-growing prevalence of type 2 diabetes in the world has necessitated an urgent need for multiple orally effective agents that can regulate glucose homeostasis with a concurrent reduction in body weight. G-Protein coupled receptor 119 (GPR119) is a GPCR target at which agonists have demonstrated glucose-dependent insulin secretion and shows beneficial effects on glycemic control. Herein, we describe our efforts leading to the identification of a potent, oral GPR-119 agonist, MK-8282, which shows improved glucose tolerance in multiple animal models and has excellent off-target profile. The key design elements in the compounds involved a combination of a fluoro-pyrimidine and a conformationally constrained bridged piperidine to impart good potency and efficacy.
Collapse
Affiliation(s)
- Santhosh F. Neelamkavil
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Andrew W. Stamford
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Timothy Kowalski
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dipshikha Biswas
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Craig Boyle
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Samuel Chackalamannil
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Yan Xia
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Charles Jayne
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Bernard Neustadt
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jinsong Hao
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Hong Liu
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xing Dai
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Hana Baker
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Brian Hawes
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Kim O’Neill
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Huadong Tang
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - William J. Greenlee
- MRL, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
7
|
Zhao Z, Pissarnitski DA, Huang X, Palani A, Zhu Z, Greenlee WJ, Hyde LA, Song L, Terracina G, Zhang L, Parker EM. Discovery of a Tetrahydrobenzisoxazole Series of γ-Secretase Modulators. ACS Med Chem Lett 2017; 8:1002-1006. [PMID: 29057041 DOI: 10.1021/acsmedchemlett.7b00178] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Accepted: 09/19/2017] [Indexed: 11/29/2022] Open
Abstract
The design and synthesis of a new series of tetrahydrobenzisoxazoles as modulators of γ-secretase activity and their structure-activity relationship (SAR) will be detailed. Several compounds are active γ-secretase modulators (GSMs) with good to excellent selectivity for the reduction of Aβ42 in the cellular assay. Compound 14a was tested in vivo in a nontransgenic rat model and was found to significantly reduce Aβ42 in the CNS compartment compared to vehicle-treated animals (up to 58% reduction of cerebrospinal fluid Aβ42 as measured 3 h after an acute oral dosing at 30 mg/kg).
Collapse
Affiliation(s)
- Zhiqiang Zhao
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dmitri A. Pissarnitski
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xianhai Huang
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Anandan Palani
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Zhaoning Zhu
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - William J. Greenlee
- Department
of Medicinal Chemistry and ‡Department of Neurobiology, Merck Research Laboratories, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | | | | | | | | | | |
Collapse
|
8
|
Wu WL, Burnett DA, Clader J, Greenlee WJ, Jiang Q, Hyde LA, Del Vecchio RA, Cohen-Williams ME, Song L, Lee J, Terracina G, Zhang Q, Nomeir A, Parker EM, Zhang L. Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors. Bioorg Med Chem Lett 2016; 26:5836-5841. [PMID: 27836402 DOI: 10.1016/j.bmcl.2016.04.095] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 04/27/2016] [Accepted: 04/28/2016] [Indexed: 11/16/2022]
Abstract
In this paper we describe our strategy to improve the aqueous solubility of SCH 900229, a potent PS1-selective γ-secretase inhibitor for the treatment of Alzheimer's disease. Incorporation of ionizable amino groups into the side chain terminal generates water soluble β-aminosulfone analogues of SCH 900229 that maintain robust in vitro potency and in vivo efficacy.
Collapse
Affiliation(s)
- Wen-Lian Wu
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Duane A Burnett
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - John Clader
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - William J Greenlee
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Qin Jiang
- Albany Molecular Research, Inc., 26 Corporate Cir, Albany, NY 12212, USA
| | - Lynn A Hyde
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | | | | | - Lixin Song
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Julie Lee
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Giuseppe Terracina
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Qi Zhang
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Amin Nomeir
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Eric M Parker
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Lili Zhang
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| |
Collapse
|
9
|
Scott JD, Li SW, Brunskill APJ, Chen X, Cox K, Cumming JN, Forman M, Gilbert EJ, Hodgson RA, Hyde LA, Jiang Q, Iserloh U, Kazakevich I, Kuvelkar R, Mei H, Meredith J, Misiaszek J, Orth P, Rossiter LM, Slater M, Stone J, Strickland CO, Voigt JH, Wang G, Wang H, Wu Y, Greenlee WJ, Parker EM, Kennedy ME, Stamford AW. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. J Med Chem 2016; 59:10435-10450. [PMID: 27933948 DOI: 10.1021/acs.jmedchem.6b00307] [Citation(s) in RCA: 113] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease. Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates and CSF Aβ levels in humans. In this annotation, we describe the discovery of 3, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core as well as aspects of its preclinical and Phase 1 clinical characterization.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Qin Jiang
- Albany Molecular Research Inc. , 26 Corporate Circle, Albany, New York 12203, United States
| | | | | | | | | | | | | | | | - Lana M Rossiter
- Albany Molecular Research Inc. , 26 Corporate Circle, Albany, New York 12203, United States
| | - Meagan Slater
- Albany Molecular Research Inc. , 26 Corporate Circle, Albany, New York 12203, United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Seganish WM, McElroy WT, Herr RJ, Brumfield S, Greenlee WJ, Harding J, Komanduri V, Matasi J, Prakash KC, Tulshian D, Yang J, Yet L, Devito K, Fossetta J, Garlisi CG, Lundell D, Niu X, Sondey C. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. Bioorg Med Chem Lett 2015; 25:3203-7. [PMID: 26115573 DOI: 10.1016/j.bmcl.2015.05.097] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 05/26/2015] [Accepted: 05/28/2015] [Indexed: 11/24/2022]
Abstract
IRAK4 plays a key role in TLR/IL-1 signaling. Previous efforts identified a series of aminopyrimidine IRAK4 inhibitors that possess good potency, but modest kinase selectivity. Exploration of substituents at the C-2 and C-5 positions generated compounds that maintained IRAK4 potency and improved kinase selectivity. Additionally, it was found that the pyrimidine core could be replaced with a pyridine and still retain potency and kinase selectivity. The optimization efforts led to compound 26 which had an IRAK4 IC50 of 0.7 nM, an IC50 of 55 nM on THP-1 cells stimulated with LPS, a TLR4 agonist, and greater than 100-fold selectivity versus 96% of a panel of 306 kinases.
Collapse
Affiliation(s)
- W Michael Seganish
- Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States.
| | - William T McElroy
- Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - R Jason Herr
- Medicinal Chemistry Department, Albany Molecular Research, Inc. (AMRI), 26 Corporate Circle, Albany, NY 12203, United States
| | - Stephanie Brumfield
- Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - William J Greenlee
- Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - James Harding
- Medicinal Chemistry Department, Albany Molecular Research, Inc. (AMRI), 26 Corporate Circle, Albany, NY 12203, United States
| | - Venukrishnan Komanduri
- Medicinal Chemistry Department, AMRI Singapore Research Centre, 61 Science Park Road, #05-01, The Galen, Science Park III, Singapore 117525, Singapore
| | - Julius Matasi
- Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - Koraboina Chandra Prakash
- Medicinal Chemistry Department, AMRI Singapore Research Centre, 61 Science Park Road, #05-01, The Galen, Science Park III, Singapore 117525, Singapore
| | - Deen Tulshian
- Discovery Chemistry, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - Jinhai Yang
- Medicinal Chemistry Department, Albany Molecular Research, Inc. (AMRI), 26 Corporate Circle, Albany, NY 12203, United States
| | - Larry Yet
- Medicinal Chemistry Department, Albany Molecular Research, Inc. (AMRI), 26 Corporate Circle, Albany, NY 12203, United States
| | - Kristine Devito
- In Vitro Pharmacology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - James Fossetta
- Respiratory and Immunology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - Charles G Garlisi
- In Vitro Pharmacology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - Daniel Lundell
- Respiratory and Immunology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - Xiaoda Niu
- In Vitro Pharmacology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| | - Christopher Sondey
- In Vitro Pharmacology, Merck Research Laboratories, 2015 Galloping Hill Rd., Kenilworth, NJ 07033, United States
| |
Collapse
|
12
|
McKittrick BA, Caldwell JP, Bara T, Boykow G, Chintala M, Clader J, Czarniecki M, Courneya B, Duffy R, Fleming L, Giessert R, Greenlee WJ, Heap C, Hong L, Huang Y, Iserloh U, Josien H, Khan T, Korfmacher W, Liang X, Mazzola R, Mitra S, Moore K, Orth P, Rajagopalan M, Roy S, Sakwa S, Strickland C, Vaccaro H, Voigt J, Wang H, Wong J, Zhang R, Zych A. Iminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors. Bioorg Med Chem Lett 2015; 25:1592-6. [DOI: 10.1016/j.bmcl.2015.02.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Revised: 01/30/2015] [Accepted: 02/02/2015] [Indexed: 10/24/2022]
|
13
|
Chelliah MV, Eagen K, Guo Z, Chackalamannil S, Xia Y, Tsai H, Greenlee WJ, Ahn HS, Kurowski S, Boykow G, Hsieh Y, Chintala M. Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar. ACS Med Chem Lett 2014; 5:561-5. [PMID: 24900880 PMCID: PMC4027741 DOI: 10.1021/ml500008w] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Accepted: 03/11/2014] [Indexed: 01/24/2023] Open
Abstract
We have synthesized several C7-spirocyclic analogues of vorapaxar and evaluated their in vitro activities against PAR-1 receptor. Some of these analogues showed activities and rat plasma levels comparable to vorapaxar. Compound 5c from this series showed excellent PAR-1 activity (K i = 5.1 nM). We also present a model of these spirocyclic compounds docked to the PAR-1 receptor based on the X-ray crystal structure of vorapaxar bound to PAR-1 receptor. This model explains some of the structure-activity relationships in this series.
Collapse
Affiliation(s)
- Mariappan V. Chelliah
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Keith Eagen
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Zhuyan Guo
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | | | | | - Hsingan Tsai
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | | | - Ho-Sam Ahn
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Stan Kurowski
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - George Boykow
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Yunsheng Hsieh
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Madhu Chintala
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| |
Collapse
|
14
|
Chelliah MV, Chackalamannil S, Xia Y, Greenlee WJ, Ahn HS, Kurowski S, Boykow G, Hsieh Y, Chintala M. Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar. ACS Med Chem Lett 2014; 5:183-7. [PMID: 24900795 DOI: 10.1021/ml400452v] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 12/18/2013] [Indexed: 11/29/2022] Open
Abstract
We have synthesized several C7-aminomethyl analogues of vorapaxar that are potent PAR-1 antagonists. Many of these analogues showed excellent in vitro binding affinity and pharmacokinetics profile in rats. Compound 6a from this series showed excellent PAR-1 activity (K i = 5 nM). We have also synthesized a C9a-hydroxy analogue of vorapaxar, which showed very good PAR-1 affinity (K i = 19.5 nM) along with excellent rat pharmacokinetic profile and ex vivo efficacy in the cynomolgus monkey.
Collapse
Affiliation(s)
- Mariappan V. Chelliah
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Samuel Chackalamannil
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Yan Xia
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - William J. Greenlee
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Ho-Sam Ahn
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Stan Kurowski
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - George Boykow
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Yunsheng Hsieh
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| | - Madhu Chintala
- Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States
| |
Collapse
|
15
|
Wu WL, Asberom T, Bara T, Bennett C, Burnett DA, Clader J, Domalski M, Greenlee WJ, Josien H, McBriar M, Rajagopalan M, Vicarel M, Xu R, Hyde LA, Del Vecchio RA, Cohen-Williams ME, Song L, Lee J, Terracina G, Zhang Q, Nomeir A, Parker EM, Zhang L. Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors. Bioorg Med Chem Lett 2013; 23:844-9. [DOI: 10.1016/j.bmcl.2012.11.047] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Revised: 11/09/2012] [Accepted: 11/14/2012] [Indexed: 01/30/2023]
|
16
|
Wu WL, Sasikumar TK, Domalski MS, Qiang L, Burnett DA, Clader J, Greenlee WJ, Chan TM, Lee J, Zhang L. A-ring modification of SCH 900229 and related chromene sulfone γ-secretase inhibitors. Bioorg Med Chem Lett 2013; 23:850-3. [PMID: 23265902 DOI: 10.1016/j.bmcl.2012.11.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Revised: 11/09/2012] [Accepted: 11/14/2012] [Indexed: 11/19/2022]
Abstract
Attempts to block metabolism by incorporating a 9-fluoro substituent at the A-ring of compound 1 (SCH 900229) using electrophilic Selectfluor™ led to an unexpected oxidation of the A-ring to give difluoroquinone analog 1a. Oxidation of other related chromene γ-secretase inhibitors 2-8 resulted in similar difluoroquinone analogs 2a-8a, respectively. These quinone products exhibited comparable in vitro potency in a γ-scretase membrane assay, but were several fold less potent in a cell-based assay in lowering Aβ40-42, compared to their parent compounds.
Collapse
Affiliation(s)
- Wen-Lian Wu
- Merck Research Laboratories, 2015 Galloping Hill Rd, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Wu WL, Domalski M, Burnett DA, Josien H, Bara T, Rajagopalan M, Xu R, Clader J, Greenlee WJ, Brunskill A, Hyde LA, Del Vecchio RA, Cohen-Williams ME, Song L, Lee J, Terracina G, Zhang Q, Nomeir A, Parker EM, Zhang L. Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease. ACS Med Chem Lett 2012; 3:892-6. [PMID: 24900404 DOI: 10.1021/ml300044f] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 04/09/2012] [Indexed: 12/13/2022] Open
Abstract
An exploration of the SAR of the side chain of a novel tricyclic series of γ-secretase inhibitors led to the identification of compound (-)-16 (SCH 900229), which is a potent and PS1 selective inhibitor of γ-secretase (Aβ40 IC50 = 1.3 nM). Compound (-)-16 demonstrated excellent lowering of Aβ after oral administration in preclinical animal models and was advanced to human clinical trials for further development as a therapeutic agent for the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Wen-Lian Wu
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Martin Domalski
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Duane A. Burnett
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Hubert Josien
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Thomas Bara
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Murali Rajagopalan
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Ruo Xu
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - John Clader
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - William J. Greenlee
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Andrew Brunskill
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Lynn A. Hyde
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Robert A. Del Vecchio
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Mary E. Cohen-Williams
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Lixin Song
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Julie Lee
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Giuseppe Terracina
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Qi Zhang
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Amin Nomeir
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Eric M. Parker
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| | - Lili Zhang
- Department
of Medicinal Chemistry, ‡Department of Neuroscience, ∥Department of Pharmaceutical Sciences, and §Department of
Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth,
New Jersey 07033, United States
| |
Collapse
|
18
|
Stamford AW, Scott JD, Li SW, Babu S, Tadesse D, Hunter R, Wu Y, Misiaszek J, Cumming JN, Gilbert EJ, Huang C, McKittrick B, Hong L, Guo T, Zhu Z, Strickland C, Orth P, Voigt J, Kennedy ME, Chen X, Kuvelkar R, Hodgson R, Hyde L, Cox K, Favreau L, Parker EM, Greenlee WJ. Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. ACS Med Chem Lett 2012; 3:897-902. [PMID: 23412139 PMCID: PMC3568987 DOI: 10.1021/ml3001165] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 07/12/2012] [Indexed: 01/16/2023] Open
Abstract
Inhibition of BACE1 to prevent brain Aβ peptide formation is a potential disease-modifying approach to the treatment of Alzheimer's disease. Despite over a decade of drug discovery efforts, the identification of brain-penetrant BACE1 inhibitors that substantially lower CNS Aβ levels following systemic administration remains challenging. In this report we describe structure-based optimization of a series of brain-penetrant BACE1 inhibitors derived from an iminopyrimidinone scaffold. Application of structure-based design in tandem with control of physicochemical properties culminated in the discovery of compound 16, which potently reduced cortex and CSF Aβ40 levels when administered orally to rats.
Collapse
Affiliation(s)
- Andrew W. Stamford
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jack D. Scott
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Sarah W. Li
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Suresh Babu
- Ligand Pharmaceuticals, Inc.,
3000 Eastpark Boulevard Cranbury, New Jersey 08512, United States
| | - Dawit Tadesse
- Ligand Pharmaceuticals, Inc.,
3000 Eastpark Boulevard Cranbury, New Jersey 08512, United States
| | - Rachael Hunter
- Ligand Pharmaceuticals, Inc.,
3000 Eastpark Boulevard Cranbury, New Jersey 08512, United States
| | - Yusheng Wu
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jeffrey Misiaszek
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jared N. Cumming
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Eric J. Gilbert
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Chunli Huang
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Brian
A. McKittrick
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Liwu Hong
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Tao Guo
- Ligand Pharmaceuticals, Inc.,
3000 Eastpark Boulevard Cranbury, New Jersey 08512, United States
| | - Zhaoning Zhu
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Corey Strickland
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Peter Orth
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Johannes
H. Voigt
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Matthew E. Kennedy
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xia Chen
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Reshma Kuvelkar
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Robert Hodgson
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Lynn
A. Hyde
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Kathleen Cox
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Leonard Favreau
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - Eric M. Parker
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| | - William J. Greenlee
- Departments
of Medicinal Chemistry, Neurobiology, Drug Metabolism, and Global Structural Chemistry, Merck Research Laboratories, 2015 Galloping
Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
19
|
Brumfield S, Korakas P, Silverman LS, Tulshian D, Matasi JJ, Qiang L, Bennett CE, Burnett DA, Greenlee WJ, Knutson CE, Wu WL, Sasikumar TK, Domalski M, Bertorelli R, Grilli M, Lozza G, Reggiani A, Li C. Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain. Bioorg Med Chem Lett 2012; 22:7223-6. [PMID: 23084894 DOI: 10.1016/j.bmcl.2012.09.048] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Revised: 09/10/2012] [Accepted: 09/17/2012] [Indexed: 11/27/2022]
Abstract
High throughput screening identified the pyridothienopyrimidinone 1 as a ligand for the metabotropic glutamate receptor 1 (mGluR1=10 nM). Compound 1 has an excellent in vivo profile; however, it displays unfavorable pharmacokinetic issues and metabolic stability. Therefore, using 1 as a template, novel analogues (10i) were prepared. These analogues displayed improved oral exposure and activity in the Spinal Nerve Ligation (SNL) pain model.
Collapse
Affiliation(s)
- Stephanie Brumfield
- Merck Research Laboratories, 2015 Galloping Hill Road, MS 2545, Kenilworth, NJ 07033-0539, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Chelliah MV, Chackalamannil S, Xia Y, Eagen K, Greenlee WJ, Ahn HS, Agans-Fantuzzi J, Boykow G, Hsieh Y, Bryant M, Chan TM, Chintala M. Discovery of nor-seco himbacine analogs as thrombin receptor antagonists. Bioorg Med Chem Lett 2012; 22:2544-9. [DOI: 10.1016/j.bmcl.2012.01.138] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Accepted: 01/31/2012] [Indexed: 12/22/2022]
|
21
|
Ho GD, Michael Seganish W, Bercovici A, Tulshian D, Greenlee WJ, Van Rijn R, Hruza A, Xiao L, Rindgen D, Mullins D, Guzzi M, Zhang X, Bleickardt C, Hodgson R. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 2012; 22:2585-9. [PMID: 22377514 DOI: 10.1016/j.bmcl.2012.01.113] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2011] [Revised: 01/25/2012] [Accepted: 01/30/2012] [Indexed: 01/08/2023]
Abstract
The identification of potent and orally active dihydroimidazoisoquinolines as PDE 10A inhibitors is reported. The SAR development led to the discovery of compound 35 as a potent, selective, and orally active PDE10A inhibitor. Compound 35 inhibited MK-801-induced hyperactivity at 3mg/kg and displayed a 10-fold separation between the minimal effective doses for inhibition of MK-801-induced hyperactivity and hypolocomotion in rats.
Collapse
Affiliation(s)
- Ginny D Ho
- Department of Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Palani A, Rao AU, Chen X, Huang X, Su J, Tang H, Huang Y, Qin J, Xiao D, Degrado S, Sofolarides M, Zhu X, Liu Z, McKittrick B, Zhou W, Aslanian R, Greenlee WJ, Senior M, Cheewatrakoolpong B, Zhang H, Farley C, Cook J, Kurowski S, Li Q, van Heek M, Wang G, Hsieh Y, Li F, Greenfeder S, Chintala M. Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett 2012; 3:63-8. [PMID: 24900372 DOI: 10.1021/ml200243g] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2011] [Accepted: 11/24/2011] [Indexed: 11/28/2022] Open
Abstract
Structure-guided optimization of a series of C-5 alkyl substituents led to the discovery of a potent nicotinic acid receptor agonist SCH 900271 (33) with an EC50 of 2 nM in the hu-GPR109a assay. Compound 33 demonstrated good oral bioavailability in all species. Compound 33 exhibited dose-dependent inhibition of plasma free fatty acid (FFA) with 50% FFA reduction at 1.0 mg/kg in fasted male beagle dogs. Compound 33 had no overt signs of flushing at doses up to 10 mg/kg with an improved therapeutic window to flushing as compared to nicotinic acid. Compound 33 was evaluated in human clinical trials.
Collapse
Affiliation(s)
- Anandan Palani
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ashwin U. Rao
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xiao Chen
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xianhai Huang
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jing Su
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Haiqun Tang
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ying Huang
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jun Qin
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Dong Xiao
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Sylvia Degrado
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Michael Sofolarides
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Xiaohong Zhu
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Zhidan Liu
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Brian McKittrick
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Wei Zhou
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Robert Aslanian
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - William J. Greenlee
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Mary Senior
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Boonlert Cheewatrakoolpong
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Hongtao Zhang
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Constance Farley
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - John Cook
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Stan Kurowski
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Qiu Li
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Margaret van Heek
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Gangfeng Wang
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Yunsheng Hsieh
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Fangbiao Li
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Scott Greenfeder
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Madhu Chintala
- Department of Medicinal Chemistry, ‡Department of Biology, and §Department of Drug Metabolism & Pharmacokinetics, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
23
|
Bennett CE, Burnett DA, Greenlee WJ, Knutson CE, Korakas P, Li C, Tulshian D, Wu WL, Bertorelli R, Fredduzzi S, Grilli M, Lozza G, Reggiani A, Veltri A. Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorg Med Chem Lett 2012; 22:1575-8. [PMID: 22266036 DOI: 10.1016/j.bmcl.2011.12.131] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2011] [Accepted: 12/29/2011] [Indexed: 10/14/2022]
Abstract
A series of fused tricyclic mGluR1 antagonists containing a pyridone ring were synthesized. In vitro, these antagonists were potent against both human and rat isozymes, as well as selective for inhibiting mGluR1 over mGluR5. When dosed orally, several examples were active in vivo in a rat SNL test.
Collapse
Affiliation(s)
- Chad E Bennett
- Merck Research Laboratories, Kenilworth, NJ 07033-0539, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Yang SW, Smotryski J, McElroy WT, Tan Z, Ho G, Tulshian D, Greenlee WJ, Guzzi M, Zhang X, Mullins D, Xiao L, Hruza A, Chan TM, Rindgen D, Bleickardt C, Hodgson R. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg Med Chem Lett 2012; 22:235-9. [DOI: 10.1016/j.bmcl.2011.11.023] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2011] [Revised: 11/04/2011] [Accepted: 11/07/2011] [Indexed: 10/15/2022]
|
25
|
Xu R, Cole D, Asberom T, Bara T, Bennett C, Burnett DA, Clader J, Domalski M, Greenlee WJ, Hyde L, Josien H, Li H, McBriar M, McKittrick B, Pissarnitski D, Qiang L, Rajagopalan M, Sasikumar T, Su J, Tang H, Wu WL, Zhang L, Zhao Z. SAR of tricyclic sulfones as γ-secretase inhibitors. Sci China Chem 2011. [DOI: 10.1007/s11426-011-4388-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
26
|
Xia Y, Chackalamannil S, Greenlee WJ, Jayne C, Neustadt B, Stamford A, Vaccaro H, Xu X(L, Baker H, O’Neill K, Woods M, Hawes B, Kowalski T. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. Bioorg Med Chem Lett 2011; 21:3290-6. [DOI: 10.1016/j.bmcl.2011.04.035] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 04/04/2011] [Accepted: 04/07/2011] [Indexed: 12/01/2022]
|
27
|
Li H, Xu R, Cole D, Clader JW, Greenlee WJ, Nomeir AA, Song L, Zhang L. Design, synthesis, and structure–activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors. Bioorg Med Chem Lett 2010; 20:6606-9. [DOI: 10.1016/j.bmcl.2010.09.028] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Revised: 09/02/2010] [Accepted: 09/07/2010] [Indexed: 10/19/2022]
|
28
|
Xia Y, Chackalamannil S, Greenlee WJ, Wang Y, Hu Z, Root Y, Wong J, Kong J, Ahn HS, Boykow G, Hsieh Y, Kurowski S, Chintala M. Discovery of a vorapaxar analog with increased aqueous solubility. Bioorg Med Chem Lett 2010; 20:6676-9. [DOI: 10.1016/j.bmcl.2010.09.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2010] [Accepted: 09/01/2010] [Indexed: 11/29/2022]
|
29
|
Sasikumar T, Qiang L, Burnett DA, Cole D, Xu R, Li H, Greenlee WJ, Clader J, Zhang L, Hyde L. Tricyclic sulfones as orally active γ-secretase inhibitors: Synthesis and structure–activity relationship studies. Bioorg Med Chem Lett 2010; 20:3632-5. [DOI: 10.1016/j.bmcl.2010.04.104] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2010] [Revised: 04/21/2010] [Accepted: 04/23/2010] [Indexed: 11/17/2022]
|
30
|
Sasikumar T, Qiang L, Burnett DA, Greenlee WJ, Li C, Grilli M, Bertorelli R, Lozza G, Reggiani A. A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorg Med Chem Lett 2010; 20:2474-7. [DOI: 10.1016/j.bmcl.2010.03.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2010] [Revised: 02/26/2010] [Accepted: 03/01/2010] [Indexed: 10/19/2022]
|
31
|
Qiang L, Sasikumar T, Burnett DA, Su J, Tang H, Ye Y, Mazzola RD, Zhu Z, McKittrick BA, Greenlee WJ, Fawzi A, Smith M, Zhang H, Lachowicz JE. Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists. Bioorg Med Chem Lett 2010; 20:836-40. [DOI: 10.1016/j.bmcl.2009.12.100] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2009] [Revised: 12/23/2009] [Accepted: 12/24/2009] [Indexed: 11/29/2022]
|
32
|
Sasikumar T, Burnett DA, Greenlee WJ, Smith M, Fawzi A, Zhang H, Lachowicz JE. Remote functionalization of SCH 39166: Discovery of potent and selective benzazepine dopamine D1 receptor antagonists. Bioorg Med Chem Lett 2010; 20:832-5. [DOI: 10.1016/j.bmcl.2009.12.094] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2009] [Revised: 12/22/2009] [Accepted: 12/24/2009] [Indexed: 11/25/2022]
|
33
|
Wang YS, Strickland C, Voigt JH, Kennedy ME, Beyer BM, Senior MM, Smith EM, Nechuta TL, Madison VS, Czarniecki M, McKittrick BA, Stamford AW, Parker EM, Hunter JC, Greenlee WJ, Wyss DF. Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical Library Design to Identify Novel μM Leads for the Development of nM BACE-1 (β-Site APP Cleaving Enzyme 1) Inhibitors. J Med Chem 2009; 53:942-50. [DOI: 10.1021/jm901472u] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yu-Sen Wang
- Schering-Plough Research Institute, 320 Bent Street, Cambridge, Massachusetts 02141
| | - Corey Strickland
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Johannes H. Voigt
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Matthew E. Kennedy
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Brian M. Beyer
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Mary M. Senior
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Elizabeth M. Smith
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Terry L. Nechuta
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Vincent S. Madison
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Michael Czarniecki
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Brian A. McKittrick
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Andrew W. Stamford
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Eric M. Parker
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - John C. Hunter
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - William J. Greenlee
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Daniel F. Wyss
- Schering-Plough Research Institute, 320 Bent Street, Cambridge, Massachusetts 02141
| |
Collapse
|
34
|
Josien H, Bara T, Rajagopalan M, Clader JW, Greenlee WJ, Favreau L, Hyde LA, Nomeir AA, Parker EM, Song L, Zhang L, Zhang Q. Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability. Bioorg Med Chem Lett 2009; 19:6032-7. [PMID: 19800786 DOI: 10.1016/j.bmcl.2009.09.055] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Accepted: 09/14/2009] [Indexed: 01/23/2023]
Abstract
A new class of 2,6-disubstituted morpholine N-arylsulfonamide gamma-secretase inhibitors was designed based on the introduction of a morpholine core in lieu or piperidine in our lead series. This resulted in compounds with improved CYP 3A4 profiles. Several analogs that were active at lowering Abeta levels in Tg CRND8 mice upon oral administration were identified.
Collapse
Affiliation(s)
- Hubert Josien
- Department of CV and CNS Medicinal Chemistry, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Yang SW, Ho G, Tulshian D, Greenlee WJ, Anthes J, Fernandez X, McLeod RL, Hey JA, Xu X. Discovery of Orally Active 3-Pyridinyl-tropane As a Potent Nociceptin Receptor Agonist for the Management of Cough. J Med Chem 2009; 52:5323-9. [DOI: 10.1021/jm9008218] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Shu-Wei Yang
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Ginny Ho
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Deen Tulshian
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - William J. Greenlee
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - John Anthes
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Xiomara Fernandez
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Robbie L. McLeod
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - John A. Hey
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| | - Xiaoying Xu
- Department of Chemical Research—CV & CNS
- Neurobiology Department of Biological Research
- Department of Drug Metabolism
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
| |
Collapse
|
36
|
Sasikumar T, Qiang L, Burnett DA, Greenlee WJ, Li C, Heimark L, Pramanik B, Grilli M, Bertorelli R, Lozza G, Reggiani A. Tricyclic thienopyridine–pyrimidones/thienopyrimidine–pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain. Bioorg Med Chem Lett 2009; 19:3199-203. [DOI: 10.1016/j.bmcl.2009.04.104] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2009] [Revised: 04/21/2009] [Accepted: 04/23/2009] [Indexed: 10/20/2022]
|
37
|
Neustadt BR, Liu H, Hao J, Greenlee WJ, Stamford AW, Foster C, Arik L, Lachowicz J, Zhang H, Bertorelli R, Fredduzzi S, Varty G, Cohen-Williams M, Ng K. Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 2008; 19:967-71. [PMID: 19109019 DOI: 10.1016/j.bmcl.2008.11.075] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2008] [Revised: 11/19/2008] [Accepted: 11/20/2008] [Indexed: 10/21/2022]
Abstract
Antagonism of the adenosine A(2a) receptor offers great promise in the treatment of Parkinson's disease. In the course of exploring pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A(2A) antagonists, which led to clinical candidate SCH 420814, we prepared 1,2,4-triazolo[1,5-c]pyrimidines with potent and selective (vs A(1)) A(2a) antagonist activity, including oral activity in the rat haloperidol-induced catalepsy model. Structure-activity relationships and plasma levels are described for this series.
Collapse
Affiliation(s)
- Bernard R Neustadt
- Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-1310, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Yang SW, Ho G, Tulshian D, Greenlee WJ, Fernandez X, McLeod RL, Eckel S, Anthes J. Structure-activity relationships of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the treatment of cough. Bioorg Med Chem Lett 2008; 18:6340-3. [PMID: 18990569 DOI: 10.1016/j.bmcl.2008.10.088] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2008] [Revised: 10/15/2008] [Accepted: 10/20/2008] [Indexed: 10/21/2022]
Abstract
A series of 3-axial-aminomethyl-N-benzhydryl-nortropane analogs have been synthesized and identified to bind to the nociceptin receptor with high affinity. Many of these analogs showed high binding selectivity over classic opioid receptors such as mu receptor. The synthesis and structure-activity relationships around the C-3 nortropane substitution are described. Selected compounds with potent oral antitussive activity in the guinea pig model are disclosed.
Collapse
Affiliation(s)
- Shu-Wei Yang
- Department of Chemical Research-CV & CNS, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M. Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity. J Med Chem 2008; 51:3061-4. [DOI: 10.1021/jm800180e] [Citation(s) in RCA: 211] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Samuel Chackalamannil
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Yuguang Wang
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - William J. Greenlee
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Zhiyong Hu
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Yan Xia
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Ho-Sam Ahn
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - George Boykow
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Yunsheng Hsieh
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Jairam Palamanda
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | | | - Stan Kurowski
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Michael Graziano
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Madhu Chintala
- Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| |
Collapse
|
40
|
Li G, Stamford AW, Huang Y, Cheng KC, Cook J, Farley C, Gao J, Ghibaudi L, Greenlee WJ, Guzzi M, van Heek M, Hwa JJ, Kelly J, Mullins D, Parker EM, Wainhaus S, Zhang X. Discovery of novel orally active ureido NPY Y5 receptor antagonists. Bioorg Med Chem Lett 2007; 18:1146-50. [PMID: 18160282 DOI: 10.1016/j.bmcl.2007.11.132] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2007] [Revised: 11/29/2007] [Accepted: 11/30/2007] [Indexed: 11/16/2022]
Abstract
We have derived a novel series of neuropeptide Y (NPY) Y5 receptor antagonists from the biphenylurea 3. Cyclohexylurea 21c, a member of the series, is a potent NPY Y5 receptor antagonist that exhibits excellent pharmacokinetic parameters in rats and dogs. On chronic oral administration to diet-induced obese rats, 21c displayed an anti-obesity profile, causing a modest reduction in food intake, a significant decrease in body weight gain, a decrease in adipose mass, and an increase in lean tissue mass.
Collapse
Affiliation(s)
- Guoqing Li
- Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road MS 2545, Kenilworth, NJ 07033-0359, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Li H, Asberom T, Bara TA, Clader JW, Greenlee WJ, Josien HB, McBriar MD, Nomeir A, Pissarnitski DA, Rajagopalan M, Xu R, Zhao Z, Song L, Zhang L. Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors. Bioorg Med Chem Lett 2007; 17:6290-4. [PMID: 17890085 DOI: 10.1016/j.bmcl.2007.09.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2007] [Revised: 08/27/2007] [Accepted: 09/04/2007] [Indexed: 11/19/2022]
Abstract
Development of cis-2,4,6-trisubstituted piperidine N-arylsulfonamides as gamma-secretase inhibitors for the potential treatment of Alzheimer's disease (AD) is reported.
Collapse
Affiliation(s)
- Hongmei Li
- Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
McBriar MD, Clader JW, Chu I, Del Vecchio RA, Favreau L, Greenlee WJ, Hyde LA, Nomeir AA, Parker EM, Pissarnitski DA, Song L, Zhang L, Zhao Z. Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors. Bioorg Med Chem Lett 2007; 18:215-9. [PMID: 17988864 DOI: 10.1016/j.bmcl.2007.10.092] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2007] [Revised: 10/24/2007] [Accepted: 10/25/2007] [Indexed: 11/18/2022]
Abstract
The design of amide and heteroaryl amide isosteres as replacements for the carbamate substructure in previously disclosed 2,6-disubstituted piperidine N-arylsulfonamides is described. In several cases, amides lessened CYP liabilities in this class of gamma-secretase inhibitors. Selected compounds showed significant reduction of Abeta levels upon oral dosing in a transgenic murine model of Alzheimer's disease.
Collapse
Affiliation(s)
- Mark D McBriar
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Wu WL, Burnett DA, Domalski M, Greenlee WJ, Li C, Bertorelli R, Fredduzzi S, Lozza G, Veltri A, Reggiani A. Discovery of Orally Efficacious Tetracyclic Metabotropic Glutamate Receptor 1 (mGluR1) Antagonists for the Treatment of Chronic Pain. J Med Chem 2007; 50:5550-3. [DOI: 10.1021/jm070590c] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Wen-Lian Wu
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Duane A. Burnett
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Martin Domalski
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - William J. Greenlee
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Cheng Li
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Rosalia Bertorelli
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Silva Fredduzzi
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Gianluca Lozza
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Alessio Veltri
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| | - Angelo Reggiani
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, and Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina, 58, 20132 Milan, Italy
| |
Collapse
|
44
|
Su J, Tang H, McKittrick BA, Gu H, Guo T, Qian G, Burnett DA, Clader JW, Greenlee WJ, Hawes BE, O'neill K, Spar B, Weig B, Kowalski T, Sorota S. Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists. Bioorg Med Chem Lett 2007; 17:4845-50. [PMID: 17604169 DOI: 10.1016/j.bmcl.2007.06.048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 06/11/2007] [Accepted: 06/13/2007] [Indexed: 10/23/2022]
Abstract
To address the hERG liability of MCHR1 antagonists such as 1 and 2, new analogs such as 4 and 5 that incorporated a polar heteroaryl group were designed and synthesized. Biological evaluation confirmed that these new analogs retained MCH R1 activity with greatly attenuated hERG liabilities as indicated in the Rb efflux assay.
Collapse
Affiliation(s)
- Jing Su
- Department of Chemical Research, Schering-Plough Research Institute K15 2545, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Josien H, Bara T, Rajagopalan M, Asberom T, Clader JW, Favreau L, Greenlee WJ, Hyde LA, Nomeir AA, Parker EM, Pissarnitski DA, Song L, Wong GT, Zhang L, Zhang Q, Zhao Z. Small conformationally restricted piperidine N-arylsulfonamides as orally active gamma-secretase inhibitors. Bioorg Med Chem Lett 2007; 17:5330-5. [PMID: 17761417 DOI: 10.1016/j.bmcl.2007.08.013] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2007] [Revised: 08/08/2007] [Accepted: 08/08/2007] [Indexed: 01/21/2023]
Abstract
The design and development of a new class of small 2,6-disubstituted piperidine N-arylsulfonamide gamma-secretase inhibitors is reported. Lowering molecular weight including the use of conformational constraint led to compounds with less CYP 3A4 liability compared to early leads. Compounds active orally in lowering Abeta levels in Tg CRND8 mice were identified as potential treatments for Alzheimer's disease.
Collapse
Affiliation(s)
- Hubert Josien
- Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07302, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Su J, McKittrick BA, Tang H, Burnett DA, Clader JW, Greenlee WJ, Hawes BE, O'Neill K, Spar B, Weig B, Kowalski T, Sorota S, Li C, Liu T. SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG. Bioorg Med Chem 2007; 15:5369-85. [PMID: 17572094 DOI: 10.1016/j.bmc.2007.05.068] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2007] [Revised: 05/23/2007] [Accepted: 05/29/2007] [Indexed: 11/18/2022]
Abstract
To improve the ex vivo potency of MCH inhibitor 1a and to address its hERG liability, a structure-activity study was carried out, focusing on three regions of the lead structure. Introduction of new side chains with basic nitrogen improved in vitro and ex vivo bindings. Many potent compounds with K(i)<10nM were discovered (compounds 6a-j) and several compounds (14-17) had excellent ex vivo binding at 6h and 24h. Attenuating the basicity of nitrogen on the side chain, and in particular, introduction of a polar group such as aminomethyl on the distal phenyl ring significantly lowered the hERG activity. Further replacement of the distal phenyl group with heteroaryl groups in the cyclohexene series provided compounds such as 28l with excellent ex vivo activity with much reduced hERG liability.
Collapse
Affiliation(s)
- Jing Su
- Department of Chemical Research, Schering-Plough Research Institute K15 2545, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Xia Y, Chackalamannil S, Clasby M, Doller D, Eagen K, Greenlee WJ, Tsai H, Agans-Fantuzzi J, Ahn HS, Boykow GC, Hsieh Y, Lunn CA, Chintala M. Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett 2007; 17:4509-13. [PMID: 17574850 DOI: 10.1016/j.bmcl.2007.06.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2007] [Accepted: 06/01/2007] [Indexed: 10/23/2022]
Abstract
The structure-activity relationship (SAR) of the vinyl pyridine region of himbacine derived thrombin receptor (PAR-1) antagonists is described. A 2-vinylpyridyl ring substituted with an aryl or a heteroaryl group at the 5-position showed the best overall PAR-1 affinity and pharmacokinetic properties. One of the newly discovered analogs bearing a 5-(3-pyridyl) substituent showed excellent PAR-1 affinity (Ki = 22 nM) and oral activity with reduced ClogP and improved off-target selectivity compared to an earlier development candidate.
Collapse
Affiliation(s)
- Yan Xia
- Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Ho GD, Bercovici A, Tulshian D, Greenlee WJ, Fawzi A, Smith Torhan A, Zhang H. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. Bioorg Med Chem Lett 2007; 17:3023-7. [PMID: 17428659 DOI: 10.1016/j.bmcl.2007.03.061] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2007] [Revised: 03/14/2007] [Accepted: 03/19/2007] [Indexed: 01/28/2023]
Abstract
A series of 4-hydroxy-4-phenylpiperidines have been synthesized and bind to the nociceptin receptor with high affinity. The synthesis and structure-activity relationships at the N-1 and C-4 are described.
Collapse
Affiliation(s)
- Ginny D Ho
- Department of Chemical Research-CV & CNS, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | |
Collapse
|
49
|
Ho GD, Bercovici A, Tulshian D, Greenlee WJ, Fawzi A, Fernandez X, McLeod RL, Smith Torhan A, Zhang H. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. Bioorg Med Chem Lett 2007; 17:3028-33. [PMID: 17420123 DOI: 10.1016/j.bmcl.2007.03.062] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2007] [Revised: 03/14/2007] [Accepted: 03/19/2007] [Indexed: 11/16/2022]
Abstract
A series of 4-[2-(aminomethyl)phenyl]-1-[bis(2-chlorophenyl)methyl]-4-hydroxypiperidine analogs has been identified as nociceptin receptor ligands. These compounds display high affinity and functional activity at the nociceptin receptor. The synthesis and structure-activity relationships at the C-4 phenyl and N-1 positions are described and the antitussive activity of a selected compound is reported.
Collapse
Affiliation(s)
- Ginny D Ho
- Department of Chemical Research-CV & CNS, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Silverman LS, Caldwell JP, Greenlee WJ, Kiselgof E, Matasi JJ, Tulshian DB, Arik L, Foster C, Bertorelli R, Monopoli A, Ongini E. 3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists. Bioorg Med Chem Lett 2007; 17:1659-62. [PMID: 17234414 DOI: 10.1016/j.bmcl.2006.12.104] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2006] [Accepted: 12/22/2006] [Indexed: 11/19/2022]
Abstract
A novel series of 3-substituted-8-aryl-[1,2,4]-triazolo[5,1-i]purin-5-amine analogs related to Sch 58261 was synthesized in order to identify potent adenosine A(2A) receptor antagonists with improved selectivity over the A(1) receptor, physiochemical properties, and pharmacokinetic profiles as compared to those of Sch 58261. As a result of structural modifications, numerous analogs with excellent in vitro binding affinities and selectivities were identified. Moreover, compound 27 displayed both superior in vitro and highly promising in vivo profiles.
Collapse
Affiliation(s)
- Lisa S Silverman
- CV & CNS Departments of Chemical Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|